News -
Check out the posts below to learn the latest updates on our progress
- December 21 2021EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene TherapiesPRNewswire
- September 22 2021EXUMA Biotech to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferencePR Newswire
- August 2 2021Building Scientific Trust Virtually
Life Science Leader - April 9 2021Subcutaneous injection of total nucleated cells rapidly isolated following four-hour peripheral whole blood exposure to CD3-directed CAR-T lentiviruses with a synthetic driver results in robust CAR-T proliferation and anti-tumor immunity
AACR Annual Meeting 2021 - February 16 2021EXUMA Biotech on NPR’s TechNation with Dr. Moira Gunn
TechNation Radio - February 5 2021Economically Viable, Same-Day Autologous Cell Therapies
Pharma's almanac - January 11 2021EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T ProgramPR Newswire
- November 11 2020EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-Conference
PR Newswire - November 9 2020Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression
SITC 35th Anniversary Annual Meeting & Pre-Conference (virtual) - October 19 2020Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors
AACR Tumor Immunology & Immunotherapy 2020